外体药物输送系统:一种新的治疗方法,向了毒性-ALI中的PD-1
Yuanlan Huang1, Gang Li1, Zeqi Chen1
1Department of Blood Transfusion, Naval Specialty Medical Center, Naval Medical University, Shanghai, 200050, People's Republic of China.
Stem cell reviews and reports
|September 5, 2024
概括
人类带介质干细胞衍生的外体细胞 (HucMSCs-EXOs) 装有抗编程细胞死亡1 (PD-1) ,称为MEP,有效治疗败血症引起的急性肺损伤 (ALI). 欧洲议员在减少炎症和改善小鼠肺部损伤方面表现优于单个成分.
科学领域:
- 生物医学工程 生物医学工程
- 免疫学 免疫学 免疫学
- 再生医学是一种再生医学.
背景情况:
- 败血症诱导的细胞因子风暴可以导致急性肺损伤 (ALI).
- 人类带介质干细胞衍生的外体细胞 (HucMSCs-EXOs) 具有免疫抑制和抗炎性质.
- 编程细胞死亡受体1 (PD-1) 对于免疫平衡至关重要.
研究的目的:
- 研究载有抗PD-1 (MEP) 的外体对败血症-ALI的协同治疗效应.
- 阐明MEP在治疗败血症-ALI.治疗中的治疗机制.
主要方法:
- 工程HucMSCs-EXOs通过加载抗PD-1来创建MEP.
- 评估MEP的治疗效果在体内 (败血性-ALI小鼠) 和体外.
- 分析炎症标记物,细胞因子水平,细胞亡,巨细胞极化和基因表达.
主要成果:
- 与单个组件相比,MEP显著改善了败血症-ALI小鼠的肺损伤指数.
- MEP降低了炎症标志物 (CRP,PCT) 和促炎细胞因子 (TNF-α,IL-1β).
- MEP增加了抗炎细胞因子 (IL-10),CD68+巨细胞,促进了M2巨细胞的两极分化,并减少了与炎症相关的基因.
结论:
- 与单独的抗PD-1或EXO相比,MEP证明了对败血性ALI的更高的治疗疗效.
- 欧盟议员有效调节免疫反应,并减少感染性ALI的炎症.
- 欧洲议会议员显示,作为治疗败血症-ALI的新型治疗剂具有前途.
相关概念视频
01:27Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:28Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...